Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.41 |
| ▸ | MC5R | P33032 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129213 | 0.80 | EPHX1 (0.48) | CYP2A6EPHX1SLC6A4MAOA | |
| SCHEMBL3123916 | 0.80 | EPHX1 (0.48) | CYP2A6EPHX1SLC6A4MAOA | |
| SCHEMBL7298579 | 0.79 | HTR2A (0.59) | HTR2AHTR2CHTR2BTACR1MC4R | |
| Hydrochloric Acid SCHEMBL7299669 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHTR2BTACR1MC4R | |
| SCHEMBL3126270 | 0.78 | TAAR1 (0.41) | CYP2A6DPP4EPHX1SLC6A4MAOA | |
| SCHEMBL5144401 | 0.74 | HTR2A (0.67) | HTR2AHTR2CHTR2BTACR1MC4R | |
| SCHEMBL3126103 | 0.73 | TAAR1 (0.48) | DPP4 | |
| SCHEMBL3129564 | 0.73 | SLC6A4 (0.54) | CYP1A2DPP4SLC6A4 | |
| SCHEMBL29910984 | 0.71 | CYP1A2 (0.47) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL31054190 | 0.71 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491537-B1 | HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF | SENJU PHARMA CO (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | HTR2A 35/4885HTR2C 37/4885HTR2B 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.